Programs

Predictive and therapeutic programs shaped for translational oncology.

MIORG’s current portfolio includes a development-stage prognostication test and a preclinical antibody program designed to address the challenge of immunotherapy resistance.

Programs described on this page are investigational or development-stage initiatives and are not approved therapies or commercial diagnostic products.
Portfolio principle

Pair better patient selection with mechanism-led combination thinking.

Predictive Immune Profiling

A predictive test designed for anti-PD1/PD-L1 response stratification.

MIORG's predictive immune profiling concept uses immune functional RNA/DNA profiling to improve prediction of patient response to anti-PD1/PD-L1 immune checkpoint therapies. It integrates a focused immune-related gene signature with tumor mutational burden for a more complete view of immune readiness than conventional single-marker approaches.

01

Intended use

Support patient selection and response prediction for anti-PD1/PD-L1 treatment decisions.

02

Technology basis

Immune-related gene signature combined with tumor mutational burden and translational interpretation.

03

Potential clinical utility

Improve stratification, reduce uncertainty, and support earlier consideration of alternative pathways.

04

Development status

Development and validation stage, with positioning for clinically relevant partnership pathways.

Target partners and customers

  • Hospitals and oncology centers seeking better immunotherapy stratification tools
  • Diagnostic companies interested in co-development or platform integration
  • Clinical and translational research partners evaluating response biomarkers
  • Biopharma teams exploring biomarker-enriched immunotherapy development
Positioning note This is presented as a development-stage prognostic platform concept. MIORG avoids overstating readiness or clinical validation beyond currently described development status.

Immune resistance problem

Tumors may evade checkpoint therapy by suppressing innate immune activity and limiting the generation of new antitumor T cells. In this context, checkpoint blockade alone may not be sufficient to restore productive immune control.

  • Innate immune impairment can weaken immune priming
  • Reduced antitumor T-cell generation can sustain resistant disease states
  • Mechanism-led combination therapy may be required to improve outcomes
MIO-36

A combination immunotherapy candidate that makes tumors more immunogenic.

MIO-36 is a therapeutic antibody program designed to increase tumor immunogenicity and help generate antitumor T cells, improving the effect of anti-PD1/PD-L1 therapy in resistant tumor models.

01

Therapeutic concept

Increase tumor immunogenicity to improve downstream T-cell generation.

02

Combination logic

Designed for use alongside anti-PD1/PD-L1 strategies rather than as a standalone checkpoint alternative.

03

Development status

Preclinical program with resistant model evidence presented as early validation, not clinical proof.

04

Partnering opportunity

Relevant to biopharma groups interested in resistance modulation and combination immunotherapy design.

MIO-36 is described as a preclinical antibody program and combination immunotherapy concept. Any efficacy discussion should be interpreted in that development-stage context.